In Brief: Baxter's HemAssist
Executive Summary
Baxter's HemAssist: Hemoglobin therapeutic cleared by FDA for Phase III trials to investigate product's effect on survival rates in patients with severe trauma, company announces Nov. 21. Trial will begin enrolling patients by early 1997 and will compare outcomes of accident and trauma victims resuscitated with current standard of care compared to those resuscitated with HemAssist in addition to current standard of care. HemAssist is also enrolling patients in a Phase III trial of HemAssist for use with surgery...